eNeurobiología - Revista electrónica

 

 

Gonzalo Emiliano Aranda Abreu¹

¹Centro de Investigaciones Cerebrales, Universidad Veracruzana, campus Xalapa.

 

Abstract

One of the world's largest pharmaceutical companies apparently will not continue research and development of new drugs against Alzheimer's disease. This situation will leave millions of people in a vulnerable situation. Drugs approved for the treatment of the disease have not been viable and patients always return to the symptoms of the disease. I am of the idea of a primarily pharmacological therapy, using already approved medications that could delay Alzheimer's disease or alleviate some of the symptoms of the disease. This therapy consists of rehabilitating the brain of the person with Alzheimer's, so that later, the drugs, such as acetylcholinesterase inhibitors and memantine act adequately in the neurons, making the treatment indicated by neurologists more effective. This therapy is not expensive and could help the patient to lead a better quality of life. I practically discussed the translational potential of various drugs that have been tested experimentally.

Keywords: Alzheimer's disease, medications, neuroinflammation, therapy.

 

*Correspondencia: Gonzalo Emiliano Aranda Abreu. Centro de Investigaciones Cerebrales/Universidad Veracruzana, Av. Luis Castelazo Ayala, s/n, Carr. Xalapa-Veracruz, México. C.P. 91190. E-mail: garanda@uv.mx

Regresar